These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28806948)

  • 21. International Prostate Symptom Score for assessing lower urinary tract dysfunction in women.
    Hsiao SM; Lin HH; Kuo HC
    Int Urogynecol J; 2013 Feb; 24(2):263-7. PubMed ID: 22588143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.
    Quivrin M; Loffroy R; Cormier L; Mazoyer F; Bertaut A; Chambade D; Martin E; Maingon P; Walker P; Créhange G
    Radiother Oncol; 2015 Nov; 117(2):258-61. PubMed ID: 26324019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Ohashi T; Mikami S; Miyajima A; Shigematsu N; Oya M
    Int J Urol; 2016 Mar; 23(3):247-52. PubMed ID: 26663514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
    BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
    Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
    Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.
    Mazeron R; Bajard A; Montbarbon X; Gassa F; Malet C; Rocher F; Clippe S; Bringeon G; Desmettre O; Pommier P
    Radiat Oncol; 2012 Mar; 7():46. PubMed ID: 22449081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer.
    Nishihara K; Nakiri M; Chikui K; Suekane S; Matsuoka K; Hattori C; Ogo E; Abe T; Matsumoto Y; Ishitake T
    Int J Urol; 2014 Jul; 21(7):658-63. PubMed ID: 24650159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
    Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy.
    Hinnen KA; Monninkhof EM; Battermann JJ; van Roermund JG; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):883-8. PubMed ID: 21300477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor.
    Charret J; Baumann AS; Eschwege P; Moreau JL; Bernier V; Falk AT; Salleron J; Peiffert D
    Brachytherapy; 2018; 17(6):888-894. PubMed ID: 30172752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
    Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability of Thai-Version Overactive Bladder Symptom Scores (OABSS) Questionnaire and the Correlations of OABSS with Voiding Diary, International Prostate Symptom Score (IPSS), and Patient Perception of Bladder Condition (PPBC) Questionnaires.
    Bunyavejchevin S
    J Med Assoc Thai; 2015 Nov; 98(11):1064-74. PubMed ID: 26817176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
    Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
    BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
    Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
    Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.